Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, will be announcing its second quarter financial results on Thursday, Nov. 13, 2014.

Angel Broking expects Sun Pharma to post sales of Rs 47.37 billion V/s Rs 41.92 billion, a growth of 13% yoy, to be both exports and domestic sales. On the operating front, the gross margin is expected to come in at 80.5% V/s 80.9%.

However, owing to a 29.5% and 39.5% yoy rise in staff cost and R&D expenditure, the operating margins (OPM) is expected to come in at 42.3% V/s 43.6% in 2QFY2014, a yoy  dip of 131bps. Thus, the Adj. net profit is expected to come in at Rs 16.70 billion, a growth of 22.6%yoy. We remain neutral on the stock, it said.

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.